ClinicalTrials.gg
CompletedNCT00332488Updated Oct 16, 2014Results posted

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

A Phase 3 interventional study of Technosphere Insulin and Metformin & Secretagogues in Diabetes Mellitus, Type 2, sponsored by Mannkind Corporation. Completed at 120 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
547
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
7th of 49
547 · median 129
Started
2004
with 4 others
Phase 3
25 of 49
none open now
Registered
7th of 49
by date
Lead sponsor
13 of 49
Mannkind Corporation

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 5 that started in 2004, is one of 25 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smokers with clinical diagnosis of Type 2 diabetes mellitus for >or= to 6 months
  • Stable regimen of metformin for > or = to 1000mg/day or maximum tolerated dose) and a secretagogue \< or = 1/2 the maximum manufacturer-recommended daily dose without any dose adjustments within the preceding 6 wks.
  • Fixed dose combination products of metformin and sulfonylurea are acceptable as long as each individual dose meets inclusion criteria
  • >or= to 7.5% and \< or= to 11.0%
  • \< or = to 40kg/m2.
  • > or = to 70%, Total Lung capacity and > or =80% DLco > or= to 70%

Exclusion criteria

Exclusion Criteria:

  • Treatment with any type of anti-diabetic therapy, other than metformin \& secretagogues within the preceding 12 weeks
  • Serum creatinine > 1.4mg/dL in female subjects and >1.5mg/dL in male subjects
  • History of , clinically proven asthma and/or any other pulmonary function testing and/or radiologic findings
  • Evidence of serious complications of diabetes (e.g. autonomic neuropathy)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
547 participants (actual)

Study arms

  • Experimental
    1

    Technosphere Insulin

    Drug: Technosphere Insulin

  • Active comparator
    2

    Metformin \& Secretagogues

    Drug: Metformin & Secretagogues

  • Experimental
    3

    Technosphere \& Metformin

    Drug: Technosphere Insulin & Metformin

Interventions

  • Inhalation, 15U/30U, prandial

  • DrugMetformin & Secretagogues

    Drug page: Metformin

    Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.

  • DrugTechnosphere Insulin & Metformin

    Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets

06

What researchers measure

Primary outcomes

  1. Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Difference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue

    (Change from baseline within TI Alone) minus (change from baseline within metformin + secretagogue)

    Time frame: Baseline to Week 12

  2. Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment)

    Time frame: Week 24

07

Results

Posted Oct 16, 2014
Limitations and caveats
Wks 12-24 was a non-randomized treatment period of the trial; outcomes were not analyzed for Wks 12-24. Safety results include entire trial; patients counted in multiple treatments for safety.

Participant flow

31 May 2006 (first subject enrolled) to 03 Mar 2008 (last subject completed. Multi-national trial conducted in Argentina, Brazil, Canada, Chile, Czech Republic, Mexico, Poland, Russian Federation, Spain, Ukraine, and USA.

Initial Treatment Phase (Weeks 0 - 12)
Participant flow — Initial Treatment Phase (Weeks 0 - 12)
MilestoneTI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + Metformin
Started183170175
Completed133152119
Not completed501856
Withdrew: Adverse event826
Withdrew: Physician decision13210
Withdrew: Withdrawal by subject211020
Withdrew: Various4020
Withdrew: Lost to follow-up130
Withdrew: Protocol violation310
Transfer Treatment Phase (Weeks 12 - 24)
Participant flow — Transfer Treatment Phase (Weeks 12 - 24)
MilestoneTI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + Metformin
Started2972254
Completed2770233
Not completed2221
Withdrew: Adverse event003
Withdrew: Lost to follow-up001
Withdrew: Physician decision003
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject228
Withdrew: Various005

Outcome measures

PrimaryDifference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue
Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Percentage of total hemoglobin
Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue
Percentage of total hemoglobinMetformin & SecretagoguesTI Inhalation Powder + Metformin
Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue-0.78 ± -0.78-0.70 ± -0.70
Statistical analysis
  • Metformin & Secretagogues vs TI Inhalation Powder + Metformin · ANCOVA · p = 0.420 · Mean difference (final values): 0.08 · 95% CI -0.11 to 0.27
SecondaryDifference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue

(Change from baseline within TI Alone) minus (change from baseline within metformin + secretagogue)

Time frame:
Baseline to Week 12
Reported as:
Mean · Percentage of total hemoglobin
Difference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue
Percentage of total hemoglobinTI Inhalation Powder AloneMetformin & Secretagogues
Difference in Change From Baseline for HbA1c Between TI Alone and Metformin+Secretagogue0.12 ± 1.3-0.76 ± 0.92
Statistical analysis
  • TI Inhalation Powder Alone vs Metformin & Secretagogues · ANCOVA · p = < 0.001 · Mean difference (final values): 0.91 · 95% CI 0.69 to 1.14Type III
SecondaryChange in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment)
Time frame:
Week 24
Reported as:
Mean · percentage of total hemoglobin
Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment)
percentage of total hemoglobinTI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + Metformin
Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment)-1.82 ± 1.114-1.23 ± 1.080-1.68 ± 1.014

Adverse events

Collected over From first dose until 30 days after last dose of study medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TI Inhalation Powder Alone—5/181 (2.8%)72/181 (39.8%)
Metformin & Secretagogues—5/166 (3%)42/166 (25.3%)
TI Inhalation Powder + Metformin—11/351 (3.1%)138/351 (39.3%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventTI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + Metformin
ATRIAL FIBRILLATIONCardiac disorders0/1812/1660/351
SUPRAVENTRICULAR TACHYCARDIACardiac disorders0/1811/1660/351
CELLULITISInfections and infestations0/1811/1660/351
LOWER LIMB FRACTUREInjury, poisoning and procedural complications0/1811/1660/351
DUPUYTREN'S CONTRACTUREMusculoskeletal and connective tissue disorders0/1811/1660/351
BLADDER NECK OBSTRUCTIONRenal and urinary disorders0/1811/1660/351
URETHRAL STRICTURERenal and urinary disorders0/1811/1660/351
ANGINA PECTORISCardiac disorders0/1811/1660/351
HYPOGLYCAEMIAMetabolism and nutrition disorders1/1810/1662/351
RETROPERITONEAL HAEMORRHAGEGastrointestinal disorders1/1810/1660/351
Most frequent other events
Most frequent other events
EventTI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + Metformin
COUGHRespiratory, thoracic and mediastinal disorders49/1816/16662/351
HYPOGLYCAEMIAMetabolism and nutrition disorders24/18121/16684/351
NASOPHARYNGITISInfections and infestations4/18113/16618/351
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations7/18112/1668/351

Baseline characteristics

Age, Continuous
Age, Continuous(years)TI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + MetforminTotal
Mean57.3 (26 to 75)57.6 (18 to 75)56.8 (37 to 77)57.2 (18 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)TI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + MetforminTotal
Female9388101282
Male847468226
Body Weight
Body Weight(kilograms)TI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + MetforminTotal
Mean86.1 ± 15.684.2 ± 16.283.9 ± 13.984.8 ± 15.27
Fasting Plasma Glucose
Fasting Plasma Glucose(milligrams per deciliter)TI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + MetforminTotal
Mean193.5 ± 52.4194.6 ± 48.5188.6 ± 49.7192.2 ± 50.23
HbA1c
HbA1c(percentage)TI Inhalation Powder AloneMetformin & SecretagoguesTI Inhalation Powder + MetforminTotal
Mean8.9 ± 0.958.9 ± 0.949.0 ± 0.978.9 ± 0.95
08

Study locations

120 sites
  • Radiant Research-Birmingham
    Birmingham, Alabama 35209, United States
  • Parkway Medical Center
    Birmingham, Alabama 35215, United States
  • Redpoint Research
    Phoenix, Arizona 85029, United States
  • Arizona Center for Clinical Research
    Phoenix, Arizona 85032, United States
  • International Clinical Research Network
    Chula Vista, California 91911, United States
  • National Jewish Medical & Research Center
    Denver, Colorado 80206, United States
  • Creekside Endocrine Associates
    Denver, Colorado 80209, United States
  • Jennifer Hone MD
    Denver, Colorado 80220, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Center for Diabetes & Endocrine Care
    Hollywood, Florida 33021, United States
  • International Research Associates LLC
    Miami, Florida 33156, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • John H Stoger Jr Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Clintell Inc
    Skokie, Illinois 60076, United States
  • James A Dicke MDPA
    Towson, Maryland 21204, United States
  • East Coast Clinical Research Inc
    Haverhill, Massachusetts 01830, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Michigan Institute of Medicine
    Livonia, Michigan 48152, United States
  • Clayton Medical Research
    St Louis, Missouri 63117, United States
  • Raidant Research-St Louis
    St Louis, Missouri 63141, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Creighton Diabetes Center
    Omaha, Nebraska 68131, United States
  • Lovelace Scientific Resources (Albuquerque)
    Albuquerque, New Mexico 87108, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • North Shore Diabetes and Endocrine Associates
    New Hyde Park, New York 11042, United States
  • Metrolina Internal Medicine
    Charlotte, North Carolina 28204, United States
  • Charlotte Clinical Research Inc
    Charlotte, North Carolina 28211, United States
  • Sensenbrenner Primary Care
    Charlotte, North Carolina 28277, United States
  • Duke Medical Center
    Durham, North Carolina 27710, United States
  • Dayton Clinical Research
    Dayton, Ohio 45406, United States
  • Providence Health Partners - Center of Clinical Research
    Dayton, Ohio 45439, United States
  • Radiant Research
    Portland, Oregon 97239, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Collierville Medical Specialists
    Collierville, Tennessee 38017, United States
  • Memphis Internal Medicine (Kathawala)
    Memphis, Tennessee 38119, United States
  • GoodLife Medical Center PLLC
    Memphis, Tennessee 38120, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • Quality Assurance Research Center Inc
    San Antonio, Texas 78205, United States
  • Clinical Trials of Texas Inc
    San Antonio, Texas 78229, United States
  • Covenant Clinic Research
    San Antonio, Texas 78229, United States
  • Diabetes & Glandular Disease Research Assoc PA
    San Antonio, Texas 78229, United States
  • SAM Clinical Research Center
    San Antonio, Texas 78229, United States
  • Cedar Research
    Tacoma, Washington 98405, United States
  • Hospital Interzonal de Agudos Pedro Fiorito
    Avellaneda, Buenos Aires B1870ARG, Argentina
  • Centro Endocrinologic Tiempo
    Buenos Aires, C1117ABH, Argentina
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1181ACH, Argentina
  • Cons Asoc de Endocrinologia
    Buenos Aires, C1425AGC, Argentina
  • CIMeL
    Buenos Aires, Argentina
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Sao Lucas da PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda
    Rio de Janeiro, 22271-100, Brazil
  • Hospital Guilherme Alvaro
    Santos, 11045-904, Brazil
  • CPClin-Centro de Pesquisas Clinicas
    Sao Paulo, 01244-030, Brazil
  • UNIFRSP
    Sao Paulo, 04020-050, Brazil
  • Hospital do Rim e Hipertensao
    Sao Paulo, 04025-011, Brazil
  • Instituto de Pesquisa Clinica e Medicina Avancada
    Sao Paulo, 05437-010, Brazil
  • Quest Clinical Trials
    Markham, Ontario L6B 1A1, Canada
  • Lifestyle Metabolism Center
    Oakville, Ontario L6H 3P1, Canada
  • Lifestyle Metabolism Center
    Thornhill, Ontario L4J 8L7, Canada
  • Lifestyle Metabolism Center
    Toronto, Ontario M4R 2G4, Canada
  • Trial Management Group Inc (Henein
    Toronto, Ontario M4T 1N5, Canada
  • Unimedico Management
    Richmond Hill, L4C 9M7, Canada
  • Hospital Padre Alberto Hurtado
    Santiago, Region Metropolitana, Chile
  • Hospital Clinico Pontificia Universidad Catolica de Chile
    Santiago, Chile
  • Hospital del Salvador
    Santiago, Chile
  • Instituto de Informacion de Tramiento y Educacion en Salud
    Santiago, Chile
  • Diabetologicka a interni ambulance
    Ostrava-Kuncice, CZE 70702, Czech Republic
  • Institute for Clinical and Exp Medicine
    Prague 4, CZE 140 21, Czech Republic
  • University Hospital Na Bulovce
    Prague 8, CZE 180 81, Czech Republic
  • Diabetologicka ambulance (Chmura)
    Ostrava, 70200, Czech Republic
  • Interní a diabetologická Outpatient
    Ostrava, 70900, Czech Republic
  • II interni klinika FN Kralovske Vinohrady
    Praha 10, 10034, Czech Republic
  • Endokrinologicky ustav
    Praha 1, 11694, Czech Republic
  • 3rd Medical Department General Faculty Hospital
    Praha 2, 12801, Czech Republic
  • Instituto Mexicano de Investigacion
    Mexico City, Durango 06700, Mexico
  • Hospital Universitario Dr Jose E Gonzalez
    Monterrey, Nuevo Leon 64460, Mexico
  • Hospital Santa Engracia-CIMA
    Garza Garcia, 66260, Mexico
  • Centro de Estudios en Diabetes
    Mexico City, 01120, Mexico
  • Hospital General de Mexico Servicio EndocrinologiaJefe Del Servicio
    Mexico City, 06726, Mexico
  • OCA-MIRC
    Monterrey, 64020, Mexico
  • Klinika Endocrinologii Diabetologii I
    Bialystock, POL 15-276, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny
    Bialystok, POL 15-435, Poland
  • Katedra I Klinika Chorob Metabolicznych Collegium Medicum Uniwersytety Jagiellonskiego
    Krakow, POL 31 501, Poland
  • Instytut Centrum Zdrowia (009) Matki Polki
    Lodz, POL 93-338, Poland
  • Spzital Kolejowy imm Wlodzimierza Roeflera
    Pruszkow, POL 05-800, Poland
  • Oddzial Kliniczny Diabetologii (009) Kliniczny nr 1 im Norberta Barlickiego Uniwersytety Meycznego
    Lodz, 90-153, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED
    Warsaw, 03 580, Poland
  • Centrum Leczenia Chorob cywilizacyjnych
    Warszawa, 02 777, Poland
  • NHI Kemerovo Regional Clinical Hospital
    Kemerovo, RUS 650061, Russian Federation
  • NI Principal Military Clinical Hospital n a academician N.N. Burdenko of the Ministry of Defense
    Moscow, RUS 105229, Russian Federation
  • NEI HPE Moscow State University of Medicine and Dentistry of FAHSD City Clinical Hospital #70
    Moscow, RUS 111399, Russian Federation
  • NI Endrocrinological Research Centre of RAMS In patient replacing technologies department
    Moscow, RUS 115478, Russian Federation
  • NI Moscow Regional Scientific Research Clinical Institute na MF Vladimirsky
    Moscow, RUS 129110, Russian Federation
  • NEI HPE Smolensk State Medical Academy of FAHSD RNHI Smolensk Regional Clinical Hospital
    Smolensk, RUS 214018, Russian Federation
  • St Petersburg NHI City Polytclinic #77 City Diabetological Center #4
    St Petersburg, RUS 193012, Russian Federation
  • Central Medical Sanitary Unit #122
    St Petersburg, RUS 194291, Russian Federation
  • TUV Medico-Military Academy
    St Petersburg, RUS 198013, Russian Federation
  • St Petersburg NHI Municipal Multi-Speciality Hospital # 2
    St. Petersburg, RUS 194354, Russian Federation
  • MHI Clinical Hospital for Emergency Care na NV Soloviev
    Yaroslavl, RUS 150003, Russian Federation
  • NHI Yaroslavl Regional Clinical Hospital
    Yaroslavl, RUS 150062, Russian Federation

Showing the first 100 of 120 sites across 11 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a primary completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 years 7 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2006
First posted
Jun 1, 2006
Start
Dec 2004
Primary completionActual
Mar 2008
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00332488
Responsible party
Sponsor
First posted
Jun 1, 2006
Start date
Dec 2004
Primary completion
Mar 2008
Results posted
Oct 16, 2014
Last update
Oct 16, 2014

Study contacts

For MannKind sponsored trials, the Overall Study Official is the Chief Scientific Officer
study director · Mannkind Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion